OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Pharmacogenetics of alcohol use disorder treatments: an update
Emily E. Hartwell, Henry R. Kranzler
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 7, pp. 553-564
Open Access | Times Cited: 29
Emily E. Hartwell, Henry R. Kranzler
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 7, pp. 553-564
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
Overview of Alcohol Use Disorder
Henry R. Kranzler
American Journal of Psychiatry (2023) Vol. 180, Iss. 8, pp. 565-572
Closed Access | Times Cited: 28
Henry R. Kranzler
American Journal of Psychiatry (2023) Vol. 180, Iss. 8, pp. 565-572
Closed Access | Times Cited: 28
Genetics of substance use disorders: a review
Joseph D. Deak, Emma C. Johnson
Psychological Medicine (2021) Vol. 51, Iss. 13, pp. 2189-2200
Open Access | Times Cited: 49
Joseph D. Deak, Emma C. Johnson
Psychological Medicine (2021) Vol. 51, Iss. 13, pp. 2189-2200
Open Access | Times Cited: 49
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2132-2139
Open Access | Times Cited: 35
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2132-2139
Open Access | Times Cited: 35
The future of translational research on alcohol use disorder
Lara A. Ray, Erica N. Grodin, Lorenzo Leggio, et al.
Addiction Biology (2020) Vol. 26, Iss. 2
Open Access | Times Cited: 35
Lara A. Ray, Erica N. Grodin, Lorenzo Leggio, et al.
Addiction Biology (2020) Vol. 26, Iss. 2
Open Access | Times Cited: 35
Systematic review and meta‐analysis of the moderating effect of rs1799971 in OPRM1, the mu‐opioid receptor gene, on response to naltrexone treatment of alcohol use disorder
Emily E. Hartwell, Richard Feinn, Paige E. Morris, et al.
Addiction (2020) Vol. 115, Iss. 8, pp. 1426-1437
Open Access | Times Cited: 33
Emily E. Hartwell, Richard Feinn, Paige E. Morris, et al.
Addiction (2020) Vol. 115, Iss. 8, pp. 1426-1437
Open Access | Times Cited: 33
Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder
Falk W. Lohoff
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 18
Falk W. Lohoff
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 18
Applying methods for personalized medicine to the treatment of alcohol use disorder.
Alena Kuhlemeier, Yasin Desai, Alexandra T. Tonigan, et al.
Journal of Consulting and Clinical Psychology (2021) Vol. 89, Iss. 4, pp. 288-300
Open Access | Times Cited: 22
Alena Kuhlemeier, Yasin Desai, Alexandra T. Tonigan, et al.
Journal of Consulting and Clinical Psychology (2021) Vol. 89, Iss. 4, pp. 288-300
Open Access | Times Cited: 22
Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice
Raye Z. Litten, Daniel E. Falk, Megan L. Ryan, et al.
Alcoholism Clinical and Experimental Research (2019) Vol. 44, Iss. 1, pp. 23-35
Closed Access | Times Cited: 23
Raye Z. Litten, Daniel E. Falk, Megan L. Ryan, et al.
Alcoholism Clinical and Experimental Research (2019) Vol. 44, Iss. 1, pp. 23-35
Closed Access | Times Cited: 23
Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease
Yi-Xiang He, Mengnan Liu, Yangyang Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Yi-Xiang He, Mengnan Liu, Yangyang Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
The genetic landscape of substance use disorders
Zachary F. Gerring, Jackson G. Thorp, Jorien L. Treur, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 11, pp. 3694-3705
Open Access | Times Cited: 2
Zachary F. Gerring, Jackson G. Thorp, Jorien L. Treur, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 11, pp. 3694-3705
Open Access | Times Cited: 2
EFFICACY OF MEDICATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD): A SYSTEMATIC REVIEW AND META-ANALYSIS CONSIDERING BASELINE AUD SEVERITY
Roberta Agabio, Hugo López‐Pelayo, Pol Bruguera, et al.
Pharmacological Research (2024) Vol. 209, pp. 107454-107454
Open Access | Times Cited: 2
Roberta Agabio, Hugo López‐Pelayo, Pol Bruguera, et al.
Pharmacological Research (2024) Vol. 209, pp. 107454-107454
Open Access | Times Cited: 2
Clinical Neuroscience of Addiction: What Clinical Psychologists Need to Know and Why
Lara A. Ray, Erica N. Grodin
Annual Review of Clinical Psychology (2021) Vol. 17, Iss. 1, pp. 465-493
Closed Access | Times Cited: 16
Lara A. Ray, Erica N. Grodin
Annual Review of Clinical Psychology (2021) Vol. 17, Iss. 1, pp. 465-493
Closed Access | Times Cited: 16
MicroRNA hsa-miR-1301-3p Regulates Human ADH6, ALDH5A1 and ALDH8A1 in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway
Xubing Wang, Yanjie Zhao, Jiao Luo, et al.
Molecular Pharmacology (2020) Vol. 98, Iss. 2, pp. 120-129
Open Access | Times Cited: 15
Xubing Wang, Yanjie Zhao, Jiao Luo, et al.
Molecular Pharmacology (2020) Vol. 98, Iss. 2, pp. 120-129
Open Access | Times Cited: 15
Association of Alcohol Use Disorder Risk With ADH1B, DRD2, FAAH, SLC39A8, GCKR, and PDYN Genetic Polymorphisms
Evangelia Legaki, D. Tsaklakidou, Alex Hatzimanolis, et al.
In Vivo (2022) Vol. 36, Iss. 5, pp. 2092-2104
Open Access | Times Cited: 6
Evangelia Legaki, D. Tsaklakidou, Alex Hatzimanolis, et al.
In Vivo (2022) Vol. 36, Iss. 5, pp. 2092-2104
Open Access | Times Cited: 6
Pharmakotherapie der Alkoholentwöhnung: Update und neue Entwicklungen
Michael Soyka, Susanne Rösner
Der Nervenarzt (2020) Vol. 92, Iss. 1, pp. 57-65
Open Access | Times Cited: 8
Michael Soyka, Susanne Rösner
Der Nervenarzt (2020) Vol. 92, Iss. 1, pp. 57-65
Open Access | Times Cited: 8
Digital Health Applications for Pharmacogenetic Clinical Trials
Hetanshi Naik, Latha Palaniappan, Euan A. Ashley, et al.
Genes (2020) Vol. 11, Iss. 11, pp. 1261-1261
Open Access | Times Cited: 8
Hetanshi Naik, Latha Palaniappan, Euan A. Ashley, et al.
Genes (2020) Vol. 11, Iss. 11, pp. 1261-1261
Open Access | Times Cited: 8
Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder
Henry R. Kranzler, Emily E. Hartwell, Richard Feinn, et al.
Drug and Alcohol Dependence (2021) Vol. 225, pp. 108762-108762
Open Access | Times Cited: 7
Henry R. Kranzler, Emily E. Hartwell, Richard Feinn, et al.
Drug and Alcohol Dependence (2021) Vol. 225, pp. 108762-108762
Open Access | Times Cited: 7
OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial
Christian S. Hendershot, Sarah S. Dermody, Jeffrey D. Wardell, et al.
Alcoholism Clinical and Experimental Research (2020) Vol. 44, Iss. 4, pp. 983-991
Open Access | Times Cited: 7
Christian S. Hendershot, Sarah S. Dermody, Jeffrey D. Wardell, et al.
Alcoholism Clinical and Experimental Research (2020) Vol. 44, Iss. 4, pp. 983-991
Open Access | Times Cited: 7
Prospects of Genetics and Epigenetics of Alcohol Use Disorder
Friederike Wedemeyer, Jakob Kaminski, Lea Zillich, et al.
Current Addiction Reports (2020) Vol. 7, Iss. 4, pp. 446-452
Open Access | Times Cited: 7
Friederike Wedemeyer, Jakob Kaminski, Lea Zillich, et al.
Current Addiction Reports (2020) Vol. 7, Iss. 4, pp. 446-452
Open Access | Times Cited: 7
Next‐generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review
Shaunna L. Clark, Emily E. Hartwell, Doo‐Sup Choi, et al.
Alcohol Clinical and Experimental Research (2024)
Closed Access
Shaunna L. Clark, Emily E. Hartwell, Doo‐Sup Choi, et al.
Alcohol Clinical and Experimental Research (2024)
Closed Access
Modern pharmacotherapy guidance for treating alcohol use disorders
Michael Soyka, Susanne Rösner
Expert Opinion on Pharmacotherapy (2024)
Closed Access
Michael Soyka, Susanne Rösner
Expert Opinion on Pharmacotherapy (2024)
Closed Access
Comparative pharmacogenetic study of disulfiram or cyanamide efficacy for alcohol dependence: the key role of dopamine neurotransmission gene polymorphisms
А.О. Кибитов, К. В. Рыбакова, V. M. Brodyansky, et al.
V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY (2024)
Open Access
А.О. Кибитов, К. В. Рыбакова, V. M. Brodyansky, et al.
V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY (2024)
Open Access
Pharmacology of Alcohol and Alcohol Use Disorder
Naoyuki Hironaka
Springer eBooks (2019), pp. 1-20
Closed Access | Times Cited: 3
Naoyuki Hironaka
Springer eBooks (2019), pp. 1-20
Closed Access | Times Cited: 3
Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics Study
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 3
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 3
Four Actionable Bottlenecks and Potential Solutions to Translating Psychiatric Genetics Research: An Expert Review
Jessica L. Bourdon, Rachel A. Davies, Elizabeth C. Long
Public Health Genomics (2020) Vol. 23, Iss. 5-6, pp. 171-183
Open Access | Times Cited: 2
Jessica L. Bourdon, Rachel A. Davies, Elizabeth C. Long
Public Health Genomics (2020) Vol. 23, Iss. 5-6, pp. 171-183
Open Access | Times Cited: 2
